The growth in the historic period can be attributed to improved understanding of methotrexate toxicity management, increased use of high-dose chemotherapy, expansion of oncology treatment centers, availability of recombinant enzyme antidotes, enhanced clinical awareness of renal toxicity risks.
The growth in the forecast period can be attributed to growing emphasis on precision oncology supportive care, rising investments in emergency oncology therapeutics, expansion of hospital oncology infrastructure, increasing adoption of rapid-response detoxification treatments, continued innovation in enzyme-based antidotes. Major trends in the forecast period include increasing use of targeted enzyme detoxification therapies, growing clinical focus on chemotherapy toxicity management, rising adoption of emergency oncology support drugs, expansion of precision supportive care treatments, strengthening hospital-based acute care protocols.
The increasing prevalence of cancer is expected to drive the growth of the Voraxaze (megludase) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is influenced by factors such as aging populations, lifestyle changes, environmental exposures, and improved detection methods. Voraxaze (megludase) is used to treat high methotrexate toxicity in cancer patients, helping reduce severe side effects during chemotherapy. For example, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases in the USA is projected to reach 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a 2.19% increase. Therefore, the growing prevalence of cancer is driving the Voraxaze market.
The expansion of oncology care centers is expected to support the growth of the Voraxaze (megludase) market. Oncology care centers are specialized facilities focused on diagnosing, treating, and managing cancer, providing services such as chemotherapy, radiation therapy, and surgery. The increasing incidence of cancer and the demand for accessible, specialized treatment are driving the growth of these centers. The expansion of oncology care centers enhances access to Voraxaze by making treatment for methotrexate toxicity more widely available to cancer patients undergoing chemotherapy. For instance, according to the National Institutes of Health (NIH), a US-based federal agency for biomedical and public health research, there were 72 National Cancer Institute (NCI)-Designated Cancer Centers in the United States in 2023, up by six centers from 2022. Therefore, the growth of oncology care centers is contributing to the expansion of the Voraxaze market.
The rise in clinical trials is expected to propel the growth of the Voraxaze (megludase) market. Clinical trials are research studies conducted with human participants to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, or diagnostic tools. The increase in clinical trials is driven by the demand for new treatments, advancements in medical research, and the need to address emerging health challenges. Clinical trials support Voraxaze by demonstrating its safety and efficacy in managing methotrexate toxicity, aiding regulatory approvals, and promoting its adoption in medical practice. For example, according to the National Institutes of Health, approximately 479,000 clinical trials were registered in the USA in 2023, up from 437,529 in 2022, representing a 9.5% increase in registered trials. Therefore, the growing number of clinical trials is driving the Voraxaze market.
Major companies operating in the voraxaze or megludase market are BTG Specialty Pharmaceuticals, SERB Pharmaceuticals.
North America was the largest region in the voraxaze or megludase market in 2025. The regions covered in the voraxaze or megludase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the voraxaze or megludase market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the voraxaze market by increasing costs of imported recombinant enzyme materials, purification equipment, sterile filling components, and specialized cold-chain logistics. Hospital-based oncology centers in North America and Europe are most affected due to reliance on globally sourced biologic inputs, while Asia-Pacific faces higher procurement costs for specialty antidote drugs. These tariffs are raising treatment acquisition costs and affecting emergency stock availability. However, they are also encouraging domestic enzyme production, regional manufacturing partnerships, and improved supply chain security for critical oncology rescue therapies.
The voraxaze or megludase market research report is one of a series of new reports that provides voraxaze or megludase market statistics, including voraxaze or megludase industry global market size, regional shares, competitors with a voraxaze or megludase market share, detailed voraxaze or megludase market segments, market trends and opportunities, and any further data you may need to thrive in the voraxaze or megludase industry. This voraxaze or megludase market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Voraxaze or Megludase (glucarpidase) is a recombinant enzyme that lowers toxic methotrexate levels in patients with delayed clearance due to kidney dysfunction. It works by converting methotrexate into inactive metabolites, which are then eliminated through non-renal pathways. Voraxaze plays a critical role in managing severe methotrexate toxicity and preventing related complications.
The primary indications for Voraxaze or Megludase are toxic plasma methotrexate, acute renal failure, and chemotherapy-related toxicity. Toxic plasma methotrexate occurs when excessive levels of methotrexate, a chemotherapy drug, accumulate in the bloodstream, leading to severe toxicity. It is distributed through hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by adult, pediatric, and elderly patients.
The voraxaze or megludase market consists of sales of glucarpidase enzyme products and supportive care products for chemotherapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to growing emphasis on precision oncology supportive care, rising investments in emergency oncology therapeutics, expansion of hospital oncology infrastructure, increasing adoption of rapid-response detoxification treatments, continued innovation in enzyme-based antidotes. Major trends in the forecast period include increasing use of targeted enzyme detoxification therapies, growing clinical focus on chemotherapy toxicity management, rising adoption of emergency oncology support drugs, expansion of precision supportive care treatments, strengthening hospital-based acute care protocols.
The increasing prevalence of cancer is expected to drive the growth of the Voraxaze (megludase) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is influenced by factors such as aging populations, lifestyle changes, environmental exposures, and improved detection methods. Voraxaze (megludase) is used to treat high methotrexate toxicity in cancer patients, helping reduce severe side effects during chemotherapy. For example, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases in the USA is projected to reach 2,001,140 in 2024, up from 1,958,310 in 2023, reflecting a 2.19% increase. Therefore, the growing prevalence of cancer is driving the Voraxaze market.
The expansion of oncology care centers is expected to support the growth of the Voraxaze (megludase) market. Oncology care centers are specialized facilities focused on diagnosing, treating, and managing cancer, providing services such as chemotherapy, radiation therapy, and surgery. The increasing incidence of cancer and the demand for accessible, specialized treatment are driving the growth of these centers. The expansion of oncology care centers enhances access to Voraxaze by making treatment for methotrexate toxicity more widely available to cancer patients undergoing chemotherapy. For instance, according to the National Institutes of Health (NIH), a US-based federal agency for biomedical and public health research, there were 72 National Cancer Institute (NCI)-Designated Cancer Centers in the United States in 2023, up by six centers from 2022. Therefore, the growth of oncology care centers is contributing to the expansion of the Voraxaze market.
The rise in clinical trials is expected to propel the growth of the Voraxaze (megludase) market. Clinical trials are research studies conducted with human participants to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, or diagnostic tools. The increase in clinical trials is driven by the demand for new treatments, advancements in medical research, and the need to address emerging health challenges. Clinical trials support Voraxaze by demonstrating its safety and efficacy in managing methotrexate toxicity, aiding regulatory approvals, and promoting its adoption in medical practice. For example, according to the National Institutes of Health, approximately 479,000 clinical trials were registered in the USA in 2023, up from 437,529 in 2022, representing a 9.5% increase in registered trials. Therefore, the growing number of clinical trials is driving the Voraxaze market.
Major companies operating in the voraxaze or megludase market are BTG Specialty Pharmaceuticals, SERB Pharmaceuticals.
North America was the largest region in the voraxaze or megludase market in 2025. The regions covered in the voraxaze or megludase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the voraxaze or megludase market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the voraxaze market by increasing costs of imported recombinant enzyme materials, purification equipment, sterile filling components, and specialized cold-chain logistics. Hospital-based oncology centers in North America and Europe are most affected due to reliance on globally sourced biologic inputs, while Asia-Pacific faces higher procurement costs for specialty antidote drugs. These tariffs are raising treatment acquisition costs and affecting emergency stock availability. However, they are also encouraging domestic enzyme production, regional manufacturing partnerships, and improved supply chain security for critical oncology rescue therapies.
The voraxaze or megludase market research report is one of a series of new reports that provides voraxaze or megludase market statistics, including voraxaze or megludase industry global market size, regional shares, competitors with a voraxaze or megludase market share, detailed voraxaze or megludase market segments, market trends and opportunities, and any further data you may need to thrive in the voraxaze or megludase industry. This voraxaze or megludase market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Voraxaze or Megludase (glucarpidase) is a recombinant enzyme that lowers toxic methotrexate levels in patients with delayed clearance due to kidney dysfunction. It works by converting methotrexate into inactive metabolites, which are then eliminated through non-renal pathways. Voraxaze plays a critical role in managing severe methotrexate toxicity and preventing related complications.
The primary indications for Voraxaze or Megludase are toxic plasma methotrexate, acute renal failure, and chemotherapy-related toxicity. Toxic plasma methotrexate occurs when excessive levels of methotrexate, a chemotherapy drug, accumulate in the bloodstream, leading to severe toxicity. It is distributed through hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by adult, pediatric, and elderly patients.
The voraxaze or megludase market consists of sales of glucarpidase enzyme products and supportive care products for chemotherapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Voraxaze or Megludase Market Characteristics
3. Voraxaze or Megludase Market Supply Chain Analysis
4. Global Voraxaze or Megludase Market Trends and Strategies
5. Voraxaze or Megludase Market Analysis of End Use Industries
7. Global Voraxaze or Megludase Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Voraxaze or Megludase Total Addressable Market (TAM) Analysis for the Market
9. Voraxaze or Megludase Market Segmentation
10. Voraxaze or Megludase Market Regional and Country Analysis
11. Asia-Pacific Voraxaze or Megludase Market
12. China Voraxaze or Megludase Market
13. India Voraxaze or Megludase Market
14. Japan Voraxaze or Megludase Market
15. Australia Voraxaze or Megludase Market
16. South Korea Voraxaze or Megludase Market
17. Western Europe Voraxaze or Megludase Market
18. UK Voraxaze or Megludase Market
19. Germany Voraxaze or Megludase Market
20. France Voraxaze or Megludase Market
21. Eastern Europe Voraxaze or Megludase Market
22. North America Voraxaze or Megludase Market
23. USA Voraxaze or Megludase Market
24. Canada Voraxaze or Megludase Market
25. South America Voraxaze or Megludase Market
26. Middle East Voraxaze or Megludase Market
27. Africa Voraxaze or Megludase Market
29. Voraxaze or Megludase Market Competitive Landscape and Company Profiles
32. Voraxaze or Megludase Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Voraxaze Or Megludase Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses voraxaze or megludase market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for voraxaze or megludase? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The voraxaze or megludase market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Toxic Plasma Methotrexate; Acute Renal Failure; Chemotherapy Toxicity2) By Distribution Channel: Hospitals; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Pediatric; Geriatric
Companies Mentioned: BTG Specialty Pharmaceuticals; SERB Pharmaceuticals
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Voraxaze or Megludase market report include:- BTG Specialty Pharmaceuticals
- SERB Pharmaceuticals
